Hosted on MSN

Abbott touts neuromodulation portfolio’s long-term benefits

Abbott has touted the potential of its neuromodulation portfolio in reducing patient and healthcare burdens associated with chronic pain following the positive results of three five-year analyses. The ...
Seeking Alpha

Abbott wins FDA expanded indication for Eterna neuromodulation device

Abbott Laboratories (NYSE:ABT) announced Thursday that the FDA approved expanded MRI labeling for its pain relief device Eterna spinal cord stimulation (SCS) system, allowing its use in patients who ...
Yahoo Finance

James T. Brunz, MD Recognized by Abbott Neuromodulation as a Spinal Cord Stimulation Center of Excellence Physician

TEA, S.D., Aug. 24, 2026 /PRNewswire/ -- James T. Brunz, MD, an interventional spine and pain physician with Orthopedic Institute (OI), has been recognized by Abbott Neuromodulation as a Spinal Cord ...
Nasdaq

Abbott (ABT) Expands in Canada With First Eterna SCS Use

Abbott ABT recently announced the first usage of its Eterna spinal cord stimulator (SCS) system in Canada. This marks a significant milestone in the company’s approach to chronic pain management. The ...
Morningstar%2c Inc.

James T. Brunz, MD Recognized by Abbott Neuromodulation as a Spinal Cord Stimulation Center of Excellence Physician

According to Abbott Neuromodulation, Dr. Brunz is a strong proponent of spinal cord stimulation therapy and has served as a consultant on product design. He has performed more than 2,000 SCS implants ...